Financial Results, Reports & Presentations

Annual Report 2019

In 2019, ViroGates achieved many significant milestones, including four new clinical routine customers, a pipeline of +50 hospitals evaluating the implementation of suPAR in clinical routine practice, and validation on all commercially relevant Roche Diagnostics cobas instruments. All these achievements are a result of the company’s core focus on commercializing its suPARnostic® products following the initial public offering in June 2018.

Click here to download ViroGates’ Annual Report 2019.

Financial Results Q1, 2020

Investor Presentations


17 June 2020:
ABGSC Conference Call with ViroGates in “Weekly Window of Opportunity”, at 14.00-14.30 CET.
CEO Jakob Knudsen will present ViroGates business and visions.